Duchenne UK has awarded £500,000 ($653,000) to biotech company MyoGene Bio to support the development of an innovative gene editing therapy for Duchenne muscular dystrophy (DMD). The funding is part of Duchenne UK’s Therapeutic Call, a competitive initiative designed to support innovative research with the potential to deliver new treatments for DMD. MyoGene Bio was awarded the financing for […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
